2016
ACR Appropriateness Criteria® Hodgkin Lymphoma—Unfavorable Clinical Stage I and II
Roberts KB, Younes A, Hodgson DC, Advani R, Dabaja BS, Dhakal S, Flowers CR, Ha CS, Hoppe BS, Mendenhall NP, Metzger ML, Plastaras JP, Shapiro R, Smith SM, Terezakis SA, Winkfield KM, Constine LS. ACR Appropriateness Criteria® Hodgkin Lymphoma—Unfavorable Clinical Stage I and II. American Journal Of Clinical Oncology 2016, 39: 384-395. PMID: 27299425, DOI: 10.1097/coc.0000000000000294.Peer-Reviewed Original ResearchConceptsHodgkin's lymphomaAppropriateness CriteriaEvidence-based treatment algorithmEarly-stage Hodgkin lymphomaAppropriateness of imagingClinical stage IRadiation treatment volumesMajor clinical trialsACR Appropriateness CriteriaRadiology Appropriateness CriteriaMultidisciplinary expert panelEvidence-based guidelinesClassic Hodgkin lymphomaInvolved-site radiotherapySpecific clinical conditionsCurrent medical literatureAppropriate treatment decisionsLong-term toxicityCurrent treatment schemesRadiation dose prescriptionUnfavorable presentationSequential chemotherapyPeer-reviewed journalsPrognostic factorsTherapy intensity
1992
Combined chemotherapy and radiotherapy for Hodgkin's disease.
Prosnitz L, Roberts K. Combined chemotherapy and radiotherapy for Hodgkin's disease. Oncology 1992, 6: 113-28; discussion 131-2, 137. PMID: 1533138.Peer-Reviewed Original ResearchConceptsHodgkin's diseaseCombined chemotherapyIntermediate-stage Hodgkin's diseaseSecond malignant neoplasmsStage Hodgkin's diseaseAdvanced Hodgkin's diseaseFrequency of relapsesSignificant adverse effectsConsolidation radiationComplete remissionConsolidation radiotherapyModality therapyCombination chemotherapyComplete responseField radiotherapyRelapse frequencyMalignant neoplasmsStandard treatmentLow doseChemotherapyRadiotherapyDiseaseRelapseAdverse effectsPatients